Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Brunswick, New Jersey 08903


RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorder that has not responded to previous treatment.

Study summary:

OBJECTIVES: - Determine the maximum tolerated dose and dose limiting toxicity of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with relapsed or refractory hematologic malignancies or bone marrow disorders. - Determine the pharmacokinetics of TPA in these patients. - Determine the effects of TPA on the cellular composition of blood and bone marrow in these patients. OUTLINE: This is a dose-escalation study. Patients receive 12-O-tetradecanoylphorbol-13-acetate (TPA) IV over 1 hour on days 1 and 8 followed by 2 weeks of rest. Courses repeat in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of TPA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. PROJECTED ACCRUAL: Approximately 36 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven relapsed or refractory hematologic malignancy or bone marrow disorder for which there is no standard curative therapy, including, but not limited to: - Myelodysplasia - Multiple myeloma - Myeloproliferative syndrome - Chronic lymphocytic leukemia - Aplastic anemia - Non-Hodgkin's lymphoma - Acute leukemia - Hodgkin's lymphoma - Chronic myelogenous leukemia PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-2 Life expectancy: - Greater than 1 month Hematopoietic: - Not specified Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST no greater than 3 times ULN Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - Cardiac ejection fraction greater than 40% Pulmonary: - FEV_1 greater than 50% predicted Other: - No active infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 10 weeks after study participation - No uncontrolled psychiatric or medical illness PRIOR CONCURRENT THERAPY: Biologic therapy: - Greater than 3 weeks since prior biologic therapy Chemotherapy: - Greater than 3 weeks since prior chemotherapy and recovered Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - No other concurrent investigational agents



Primary Contact:

Study Chair
Roger Strair, MD, PhD
Cancer Institute of New Jersey

Backup Contact:


Location Contact:

New Brunswick, New Jersey 08903
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.